Viridian Therapeutics, Inc.\DE
VRDN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$22.37
KIRA · Stoqly’s AI analyst, in plain words
- Viridian Therapeutics, Inc.\DE had $70.8M of revenue in fiscal 2025, up 23,359.9% on the year before. Over five years, revenue changed +132.2% a year on average.
- Its operating margin was −512.9%, up 98,505.3 pts: of every 100 in sales, about −513 is left after running the business.
- Viridian Therapeutics, Inc.\DE lost $343M in fiscal 2025.
- Free cash flow was −$277M in fiscal 2025, −390.8% of revenue.
Market cap
—
P/E
—
Revenue
$70.8M
Net income
−$343M
Free cash flow
−$277M
Operating margin
−512.9%
Viridian Therapeutics, Inc.\DE in 30 seconds · fiscal 2025
Are sales growing?
+23,359.9%
Yes. Sales grew 23,359.9% last year.
Does it make a profit?
−483.6%
No. It lost money last year.
Does profit turn into cash?
−390.8%
No. It spent more cash than it brought in.
What Viridian Therapeutics, Inc.\DE does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Viridian Therapeutics, Inc.\DE
- CIK
- 0001590750
Viridian Therapeutics, Inc.\DE · VRDN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.0M | $1.8M | $0.3M | $0.3M | $70.8M |
| Revenue growth | 182.2% | −40.2% | −82.3% | −3.8% | 23,359.9% |
| Operating margin | −2,690.8% | −7,579.2% | −81,035.0% | −99,018.2% | −512.9% |
| Net income | −$79.4M | −$130M | −$238M | −$270M | −$343M |
| Net margin | −2,680.2% | −7,329.2% | −75,711.5% | −89,387.1% | −483.6% |
| Diluted EPS | −$6.66 | −$4.05 | −$5.31 | — | — |
| Cash | |||||
| Cash from operations | −$54.6M | −$93.8M | −$184M | −$232M | −$276M |
| Capital expenditure | $0.3M | $0.8M | $0.9M | $0.5M | $0.5M |
| Free cash flow | −$54.9M | −$94.6M | −$185M | −$233M | −$277M |
| FCF margin | −1,853.5% | −5,340.6% | −58,938.9% | −77,096.0% | −390.8% |
| Share count change | 235.1% | 169.2% | 39.5% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $197M | $425M | $477M | $718M | $875M |
| Debt incl. finance leases | $0.0M | $4.6M | $20.2M | $20.6M | — |
| Shareholders' equity | $188M | $395M | $442M | $672M | $722M |
| Current ratio | 14.7x | 12.9x | 18.3x | 15.4x | 12.6x |
| Interest coverage | — | −268.6x | −191.2x | −136.1x | −73.4x |
| Returns and quality | |||||
| Return on equity | −51.6% | −44.6% | −56.8% | −48.5% | −49.2% |
| Return on tangible equity | −42.3% | −32.9% | −53.8% | −40.2% | −47.4% |
| Piotroski F-score | 4 | 2 | 2 | 3 | — |
| Altman Z'' | 10.0 | 10.6 | 7.4 | 9.0 | 2.7 |
Insiders bought, 12 months
$20.0M
1 insider
Insiders sold, 12 months
$0.4M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Viridian Therapeutics, Inc.\DE · VRDN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $22.37 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001590750). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.